Epizyme Inc
F:EPE
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Epizyme Inc
Income from Continuing Operations
Epizyme Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Epizyme Inc
F:EPE
|
Income from Continuing Operations
-$207.7m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$5.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$113m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-36%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$4.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
-$479.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4.7B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
30%
|
|
Epizyme Inc
Glance View
Epizyme Inc. is a pioneering biopharmaceutical company focused on developing innovative therapies to treat cancer and other serious diseases through the modulation of epigenetics. Founded in 2008, Epizyme has positioned itself at the forefront of this burgeoning field, leveraging its unique expertise in the study of gene expression regulation. The company’s leading product candidate, tazemetostat, has shown promise in clinical trials for treating various forms of solid tumors, including epithelioid sarcoma and certain types of non-Hodgkin lymphoma. With a strong pipeline of investigational drugs that target specific genetic mutations, Epizyme aims to provide personalized treatment options that address the underlying causes of disease, which sets it apart in a competitive marketplace. Investors should take note of Epizyme's strategic partnerships and collaborations that enhance its research capabilities and commercial reach. The company has garnered significant attention on Wall Street and among healthcare professionals, particularly after the FDA's accelerated approval of tazemetostat, signaling a shift in how targeted therapies can transform treatment paradigms in oncology. As Epizyme continues to expand its portfolio and advance its clinical trials, it stands to benefit from the growing demand for innovative cancer therapies. With a commitment to scientific excellence and a vision for transforming patient care, Epizyme Inc. is not just a biotech firm—it's a potential leader in the next era of cancer treatment, making it a compelling consideration for investors looking for opportunities in the healthcare sector.
See Also
What is Epizyme Inc's Income from Continuing Operations?
Income from Continuing Operations
-207.7m
USD
Based on the financial report for Jun 30, 2022, Epizyme Inc's Income from Continuing Operations amounts to -207.7m USD.
What is Epizyme Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-12%
Over the last year, the Income from Continuing Operations growth was 19%. The average annual Income from Continuing Operations growth rates for Epizyme Inc have been -15% over the past three years , -12% over the past five years .
You don't have any saved screeners yet
